SOFTOX $SOFTX HAS COMPLETED ENROLMENT INTO #SWIS STUDY
SOFTOX HAS COMPLETED ENROLMENT OF SOFTOX WOUND IRRIGATION SOLUTION CONFIRMATORY STUDY (SWIS-02)
SoftOx Solutions AS ("SoftOx") is pleased to announce that the enrolment of
study participants for the clinical investigation «SWIS-02» has been completed.
The study, which has been conducted at Bispebjerg University Hospital is a
confirmatory clinical investigation to document safety and performance of SoftOx
Wound Irrigation Solution ("SWIS") compared to Normal Saline (NS) in a human
wound model. It is a confirmative study and last of two clinical studies on "SWIS".
We are very pleased to have completed this enrolment because of the ongoing
lockdown in Denmark, which were affecting our recruitment pace. "With this
pivotal trial we are eagerly looking forward to examining and analyse the study
data and report on the results later in Q2-2021", says Glenn Gundersen, Medical
Director of SoftOx.
SWIS is under development to become a medical device intended for wound rinsing
and moistening to prevent infections in all types of acute wounds, such as
abrasions, cuts, burns and surgical wounds.
Antibiotic
Synthetic Biologics Bullish MomentumSynthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol.
A previously completed placebo-controlled Phase 2b clinical trial of 412 patients demonstrated SYN-004 protected the gut microbiome from antibiotic-mediated dysbiosis. Patients receiving SYN-004 also demonstrated significantly better maintenance and recovery of the gut microbiome as well as lower incidences of new colonization by opportunistic and potentially pathogenic microorganisms such as VRE. (Source: prnewswire.com)
Please leave me a message if you want to test the buy and sell indicators that i am using.